| ［1］ BamholtzSloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System［J］. J Clin Oncol, 2004, 22(14): 28652872.
［2］ Bajard A, Westeel V, Dubiez A, et al. Multivariate analysis of factors predictive of brain metastases in localized nonsmall cell lung carcinoma［J］. Lung Cancer, 2004, 45(3): 317323.
［3］ Nieder C, Norum J, Stemland JG, et al. Resource utilization in patients with brain metastases managed with best supportive care, radiotherapy and/or surgical resection: a Markov analysis［J］. Oncology, 2010, 78(56): 348355. DOI: 10.1159/000320347.
［4］ Saito EY, Viani GA, Ferrigno R, et al. Whole brain radiation therapy in management of brain metastasis: results and prognostic factors［J］. Radiat Oncol, 2006, 1: 20.
［5］ Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ results of the RTOG 9508 randomised trial［J］. Lancet, 2004, 363(9422): 16651672.
［6］ 丁巍, 王晓萍, 刘丽, 等. 脑转移瘤调强同步推量照射与适形序贯推量照射的剂量学研究［J］. 临床肿瘤学杂志, 2012, 17(9): 845847.
［7］ Baker SD, Wirth M, Statkevich P, et al. Absorption, metabolism, and excretion of 14Ctemozolomide following oral administration to patients with advanced cancer［J］. Clin Cancer Res, 1999, 5(2): 309 317.
［8］ Stupp R, Gander M, Leyvraz S, et al. Current and future developments in the use of temozolomide for the treatment of brain tumours［J］. Lancet Oncol, 2001, 2(9): 552 560.
［9］ GamboaVignolle C, FerrariCarballo T, Arrieta , et al. Wholebrain irradiation with concomitant daily fixeddose temozolomide for brain metastases treatment: a randomised phase Ⅱ trial［J］. Radiother Oncol, 2012, 102(2): 187191.
［10］ 黄骏. 口服替莫唑胺同步放射治疗脑转移瘤的疗效与安全性探讨［J］. 中国实用神经疾病杂志, 2013, 16(19): 8889.
［11］ 卓龙泉. 放疗联合替莫唑胺化疗治疗非小细胞肺癌脑转移的疗效评价［D］. 吉林: 吉林大学, 2013.
［12］ 毕卓菲, 刘宜敏, 何艳, 等. 替莫唑胺联合全脑放疗治疗脑转移瘤的疗效评价［J］. 中国新药杂志, 2012, 21(4): 412418. |
